Inhibition of translation by cytotrienin A - A member of the ansamycin family

RNA

Volumn 16, Issue 12, 2010, Pages 2404-2413

  Lindqvist, Lisa ^a   Robert, Francis ^a   Merrick, William ^b   Kakeya, Hideaki ^c   Fraser, Christopher ^d   Osada, Hiroyuki ^e   Pelletier, Jerry ^a,f  

^a MCGILL UNIVERSITY   (Canada)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KYOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e RIKEN   (Japan)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Cytotrienin A; eEF1A; Protein synthesis; Translation inhibitor

Indexed keywords

ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; CYTOTRIENIN A; ELONGATION FACTOR 1ALPHA; HEAT SHOCK PROTEIN 90; NATURAL PRODUCT; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; ASSAY; CHORIOALLANTOIS; EUKARYOTE; HUMAN; HUMAN CELL; MICROVASCULATURE; PRIORITY JOURNAL; PROKARYOTE; PROTEIN FUNCTION; PROTEIN SYNTHESIS;

EUKARYOTA; PROKARYOTA;

EID: 78649662608     PISSN: 13558382     EISSN: 14699001     Source Type: Journal    
DOI: 10.1261/rna.2307710     Document Type: Article

References (45)

1. Ahuja D, Vera MD, SirDeshpande BV, Morimoto H, Williams PG, Joullie MM, Toogood PL. 2000. Inhibition of protein synthesis by didemnin B: How EF-1α mediates inhibition of translocation. Biochemistry 39: 4339-4346.
2. Andersen GR, Nissen P, Nyborg J. 2003. Elongation factors in protein biosynthesis. Trends Biochem Sci 28: 434-441.
3. Bordeleau ME, Mori A, Oberer M, Lindqvist L, Chard LS, Higa T, Belsham GJ, Wagner G, Tanaka J, Pelletier J. 2006. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat Chem Biol 2: 213-220.
4. Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R, Bourdeau A, Brem B, Teodoro JG, Greger H, Tremblay ML, et al. 2009. Antitumor activity and mechanism of action of the cyclopenta[ b]benzofuran, silvestrol. PLoS ONE 4: e5223. doi: 10.1371/journal.pone.0005223.
5. Chan J, Khan SN, Harvey I, Merrick W, Pelletier J. 2004. Eukaryotic protein synthesis inhibitors identified by comparison of cytotoxicity profiles. RNA 10: 528-543. (Pubitemid 38241012)
6. Chao JR, Wang JM, Lee SF, Peng HW, Lin YH, Chou CH, Li JC, Huang HM, Chou CK, Kuo ML, et al. 1998. mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response. Mol Cell Biol 18: 4883-4898.
7. Crews CM, Collins JL, Lane WS, Snapper ML, Schreiber SL. 1994. GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha. J Biol Chem 269: 15411-15414.
8. Duncan R, Milburn SC, Hershey JW. 1987. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF- 4F. J Biol Chem 262: 380-388.
9. Floss HG, Yu TW. 2005. Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev 105: 621-632.
10. Fraser CS, Berry KE, Hershey JW, Doudna JA. 2007. eIF3j is located in the decoding center of the human 40S ribosomal subunit. Mol Cell 26: 811-819.
11. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, et al. 2007. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117: 2638-2648.
12. Heffron SE, Jurnak F. 2000. Structure of an EF-Tu complex with a thiazolyl peptide antibiotic determined at 2.35 Åresolution: Atomic basis for GE2270A inhibition of EF-Tu. Biochemistry 39: 37-45.
13. Heys SD, Park KG, McNurlan MA, Calder AG, Buchan V, Blessing K, Eremin O, Garlick PJ. 1991. Measurement of tumour protein synthesis in vivo in human colorectal and breast cancer and its variability in separate biopsies from the same tumour. Clin Sci 80: 587-593.
14. Isaacs JS, Xu W, Neckers L. 2003. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3: 213-217.
15. Kahns S, Lund A, Kristensen P, Knudsen CR, Clark BF, Cavallius J, Merrick WC. 1998. The elongation factor 1 A-2 isoform from rabbit: Cloning of the cDNA and characterization of the protein. Nucleic Acids Res 26: 1884-1890.
16. Kakeya H, Zhang HP, Kobinata K, Onose R, Onozawa C, Kudo T, Osada H. 1997. Cytotrienin A, a novel apoptosis inducer in human leukemia HL-60 cells. J Antibiot 50: 370-372.
17. Kakeya H, Onose R, Osada H. 1998. Caspase-mediated activation of a 36-kDa myelin basic protein kinase during anticancer druginduced apoptosis. Cancer Res 58: 4888-4894.
18. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. 1988. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 107: 1589-1598.
19. Le Tourneau C, Raymond E, Faivre S. 2007. Aplidine: A paradigm of how to handle the activity and toxicity of a novel marine anticancer poison. Curr Pharm Des 13: 3427-3439.
20. Lindqvist L, Pelletier J. 2009. Inhibitors of translation initiation as cancer therapeutics. Future Med Chem 1: 1709-1722.
21. Lorsch JR, Herschlag D. 1999. Kinetic dissection of fundamental processes of eukaryotic translation initiation in vitro. EMBO J 18: 6705-6717.
22. Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, et al. 2009. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 113: 4656-4666.
23. Marco E, Martin-Santamaria S, Cuevas C, Gago F. 2004. Structural basis for the binding of didemnins to human elongation factor eEF1A and rationale for the potent antitumor activity of these marine natural products. J Med Chem 47: 4439-4452.
24. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al. 1991. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766.
25. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, Wang X. 2003. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 17: 1475-1486.
26. Novac O, Guenier AS, Pelletier J. 2004. Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen. Nucleic Acids Res 32: 902-915.
27. Odom OW, Picking WD, Hardesty B. 1990. Movement of tRNA but not the nascent peptide during peptide bond formation on ribosomes. Biochemistry 29: 10734-10744.
28. Pelletier J, Peltz SW. 2007. Therapeutic Opportunities in Translation. In Translational Control in Biology and Medicine, (ed. MB Mathews et al.), pp. 855-895. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
29. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, et al. 2007. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109: 248-255.
30. Quintas-Cardama A, Kantarjian H, Cortes J. 2009. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 115: 5382-5393.
31. Riboldi E, Musso T, Moroni E, Urbinati C, Bernasconi S, Rusnati M, Adorini L, Presta M, Sozzani S. 2005. Cutting edge: Proangiogenic properties of alternatively activated dendritic cells. J Immunol 175: 2788-2792.
32. Robert F, Gao HQ, Donia M, Merrick WC, Hamann MT, Pelletier J. 2006. Chlorolissoclimides: New inhibitors of eukaryotic protein synthesis. RNA 12: 717-725.
33. Robert F, Carrier M, Rawe S, Chen S, Lowe S, Pelletier J. 2009. Altering chemosensitivity by modulating translation elongation. PLoS ONE 4: e5428. doi: 10.1371/journal.pone.0005428.
34. Rodnina MV, Wintermeyer W. 2001. Fidelity of aminoacyl-tRNA selection on the ribosome: Kinetic and structural mechanisms. Annu Rev Biochem 70: 415-435.
35. Schmeing TM, Voorhees RM, Kelley AC, Gao YG, Murphy FV IV, Weir JR, Ramakrishnan V. 2009. The crystal structure of the ribosome bound to EF-Tu and aminoacyl-tRNA. Science 326: 688-694.
36. Schneider-Poetsch T, Ju J, Eyler DE, Dang Y, Bhat S, Merrick WC, Green R, Shen B, Liu JO. 2010. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat Chem Biol 6: 209-217.
37. SirDeshpande BV, Toogood PL. 1995. Mechanism of protein synthesis inhibition by didemnin B in vitro. Biochemistry 34: 9177-9184.
38. Stanley WM Jr. 1974. Specific aminoacylation of the methionine-specific tRNA's of eukaryotes. Methods Enzymol 29: 530-547.
39. Taraboletti G, Poli M, Dossi R, Manenti L, Borsotti P, Faircloth GT, Broggini M, D'Incalci M, Ribatti D, Giavazzi R. 2004. Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer 90: 2418-2424. (Pubitemid 38961909)
40. Thornton S, Anand N, Purcell D, Lee J. 2003. Not just for housekeeping: Protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med 81: 536-548.
41. Urdiales JL, Morata P, Nunez De Castro I, Sanchez-Jimenez F. 1996. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett 102: 31-37.
42. Watabe M, Kakeya H, Onose R, Osada H. 2000. Activation of MST/ Krs and c-Jun N-terminal kinases by different signaling pathways during cytotrienin A-induced apoptosis. J Biol Chem 275: 8766-8771.
43. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337. (Pubitemid 38418805)
44. Wolf H, Chinali G, Parmeggiani A. 1977. Mechanism of the inhibition of protein synthesis by kirromycin. Role of elongation factor Tu and ribosomes. Eur J Biochem 75: 67-75. (Pubitemid 8080815)
45. Wurmbach P, Nierhaus KH. 1979. Codon-anticodon interaction at the ribosomal P (peptidyl-tRNA) site. Proc Natl Acad Sci 76: 2143-2147. (Pubitemid 9184897)